Previous 10 | Next 10 |
2023-09-26 13:46:32 ET Gainers: Soleno Therapeutics ( SLNO ) +446% . Femasys ( FEMY ) +271% . Immunovant ( IMVT ) +101% . Intercept Pharmaceuticals ( ICPT ) +79% . Acasti Pharma ( ACST ) +35% . Applied Therapeutics ( APLT ...
2023-09-26 12:51:44 ET Shares of Soleno Therapeutics (NASDAQ: SLNO) were up more than 372% as of 12:30 p.m. on Tuesday. The clinical stage biotech said its lead pipeline candidate fared well in a study to treat a rare genetic disorder. So far this year, the stock is up more than...
2023-09-26 12:15:20 ET DENVER, Colo., Sept 26, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual midday volume; Soleno Therapeutics (NASDAQ: SLNO), Femasys (NASDAQ: FEMY), Immunovant (NASDAQ: IMVT), Bullfrog AI (NA...
2023-09-26 10:44:29 ET More on Soleno Therapeutics Seeking Alpha’s Quant Rating on Soleno Therapeutics Historical earnings data for Soleno Therapeutics Financial information for Soleno Therapeutics For further details see: Soleno surges on data for...
Shares of Soleno Therapeutics, Inc. (NASDAQ: SLNO) traded at a new 52-week high today and are currently trading at $22.92. So far today, approximately 20.61M shares have been exchanged, as compared to an average 30-day volume of 107.67k shares. Soleno Therapeutics, Inc., a clinical-stage biop...
2023-09-26 10:00:07 ET DENVER, Colo., Sept 26, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual volume; Soleno Therapeutics (NASDAQ: SLNO), Femasys (NASDAQ: FEMY), Immunovant (NASDAQ: IMVT), Bullfrog AI (NASDAQ: B...
2023-09-26 08:21:55 ET Gainers: Soleno Therapeutics ( SLNO ) +154% . announces positive statistically significant top-line results from randomized withdrawal period of study C602 of DCCR for prader-willi syndrome. Immunovant ( IMVT ) +64% announces positive ini...
Study Met Primary Endpoint; Highly Statistically Significant Difference in Change from Baseline in HQ-CT Total Score for DCCR Compared to Placebo (p=0.0022) Soleno Intends to Submit a New Drug Application for DCCR in PWS Mid-Year 2024 Company to Host Conference Call and Webcast ...
2023-09-25 09:59:16 ET More on Health Care Select Sector SPDR BofA Securities: Which small cap non-earner stocks to avoid Health Care Select Sector SPDR ETF declares quarterly distribution of $0.5395 BofA clients were net buyers of U.S. equities for a fifth consecuti...
REDWOOD CITY, Calif., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Offi...
News, Short Squeeze, Breakout and More Instantly...
Soleno Therapeutics Inc. Company Name:
SLNO Stock Symbol:
NASDAQ Market:
Soleno Therapeutics Inc. Website:
REDWOOD CITY, Calif., June 28, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the submission of a New Drug Application (NDA) to...
2024-06-24 16:08:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
REDWOOD CITY, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it is set to join the broad-market Russell 3...